9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed

ConditionMalignant MesotheliomaEstimated Enrollment: 25Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Primary Purpose: TreatmentStudy ID Numbers: EORTC-08992Study First Received: January 28, 2000Last Updated: July 17, 2012Estimated Primary Completion Date: June 2001Primary Outcome Measures:Sponsors and Collaborators:European Organisation for Research and Treatment of Cancer - EORTCResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00004254...

Continue reading

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 69Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: NCCTG-N0021|CDR0000068659Study First Received: June 6, 2001Last Updated: December 5, 2016Estimated Primary Completion Date: August 2004Primary Outcome Measures:time to progression|survival|quality of lifeSponsors and Collaborators:Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)Result Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00017186...

Continue reading

Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 48Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 7214|H3E-US-JMFZStudy First Received: May 28, 2003Last Updated: January 24, 2007Estimated Primary Completion Date: nullPrimary Outcome Measures:To determine the objective tumor response rate for pemetrexed plus gemcitabine every 21 days in patients with malignant pleural mesothelioma who have not received prior chemotherapy|To assess time to objective tumor response for responding patients;To assess duration of response for responding patients;To assess time to treatment failure;To assess time to progressive disease|To assess progression-free survival;To assess overall...

Continue reading

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 53Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: AVF3442SStudy First Received: February 22, 2006Last Updated: November 4, 2016Estimated Primary Completion Date: June 2010Primary Outcome Measures:Progression Free Survival Rate at 6 Months|Response Rate|Overall SurvivalSponsors and Collaborators:University of Texas Southwestern Medical Center|University of Chicago|Columbia University|Duke UniversityResult Received: October 18, 2013Website Link: https://ClinicalTrials.gov/show/NCT00295503...

Continue reading

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 23Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: 1839IL/0094Study First Received: November 6, 2008Last Updated: June 5, 2012Estimated Primary Completion Date: April 2008Primary Outcome Measures:To assess the activity of ZD1839 in patients with malignant mesothelioma by estimating the objective response rate (CR and PR) at trial closure|To further characterize the safety profile of ZD1839 at a 250mg daily dose|To estimate PFS (progression free survival)|To estimate overall survival|To estimate duration of responseSponsors and Collaborators:AstraZenecaResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00787410...

Continue reading

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

ConditionPeritoneal MesotheliomasEstimated Enrollment: 19Age Group: Child, Adult, SeniorGender: AllStudy Type: ObservationalStudy Design Allocation: Observational Model: Case-Crossover|Time Perspective: RetrospectiveStudy ID Numbers: Maisonneuve Rosemont Hospital|12112Study First Received: March 12, 2013Last Updated: March 15, 2013Estimated Primary Completion Date: March 2013Primary Outcome Measures:Overall survival|Disease-Free survivalSponsors and Collaborators:Maisonneuve-Rosemont HospitalResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT01812148...

Continue reading

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

ConditionMalignant MesotheliomaEstimated Enrollment: 46Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CALGB-30601|U10CA031946|CDR0000558362Study First Received: July 30, 2007Last Updated: July 11, 2016Estimated Primary Completion Date: February 2010Primary Outcome Measures:24 Week Progression Free Survival|Number of Participants With Overall Tumor Response|Overall Survival|Progression Free SurvivalSponsors and Collaborators:Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)Result Received: December 11, 2012Website Link: https://ClinicalTrials.gov/show/NCT00509041...

Continue reading

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

ConditionMesotheliomaEstimated Enrollment: 32Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: CDR0000401795|U10CA021115|E1B03Study First Received: January 7, 2005Last Updated: November 30, 2012Estimated Primary Completion Date: September 2009Primary Outcome Measures:Best Overall Response by RECIST Criteria (Version 1.0)|Overall Survival|Progression-Free SurvivalSponsors and Collaborators:Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment GroupResult Received: February 12, 2010Website Link: https://ClinicalTrials.gov/show/NCT00101283...

Continue reading

Dendritic Cell-based Immunotherapy in Mesothelioma

ConditionMalignant Pleural MesotheliomaEstimated Enrollment: 10Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: TreatmentStudy ID Numbers: MEC-2005-269|PMR-MM05-001Study First Received: January 20, 2006Last Updated: November 15, 2010Estimated Primary Completion Date: September 2009Primary Outcome Measures:safety|tolerabilitySponsors and Collaborators:Erasmus Medical CenterResult Received: No Study Results PostedWebsite Link: https://ClinicalTrials.gov/show/NCT00280982...

Continue reading

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

ConditionMesothelioma|Lung CancerEstimated Enrollment: 662Age Group: 18 Years and older   (Adult, Senior)Gender: AllStudy Type: InterventionalStudy Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: TreatmentStudy ID Numbers: 0683-014|2005_010|CTRI/2009/091/000146Study First Received: August 5, 2005Last Updated: April 17, 2015Estimated Primary Completion Date: July 2011Primary Outcome Measures:Overall survival|Number of participants with adverse events characterized as Grade 3/4 according to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE)|Progression-free survival|Objective response rate|Percent change from baseline in dyspnea score of the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)|Percent change from baseline in forced vital capacity (FVC)Sponsors and Collaborators:Merck Sharp & Dohme Corp.Result...

Continue reading